Listeria monocytogenes est l'un des meilleurs organismes modèles pour l'étude des interactions bactérie-hôte. Ce pathogène intracellulaire facultatif peut infecter, survivre et se répliquer dans le cytoplasme des cellules eucaryotes, démontrant la co-évolution étroite de Listeria avec son hôte. Le style de vie intracellulaire de ce pathogène implique la manipulation de divers composants de la cellule hôte, dont l'un est la chromatine. En induisant des modifications de la chromatine au niveau des histones, Listeria peut influencer le programme transcriptionnel de l'hôte. Ce projet de thèse porte sur une modification spécifique des histones, la désacétylation de la lysine 18 de l'histone H3, induite par la désacétylase de l'hôte Sirtuin 2 (SIRT2) lors de sa relocalisation du cytoplasme vers le noyau pendant l'infection. Le détournement de SIRT2 par Listeria fournit un système idéal pour étudier les mécanismes de la localisation subcellulaire de SIRT2, qui est mal comprise, et c'est le but de cette thèse. En utilisant la spectrométrie de masse, nous avons identifié une nouvelle modification posttraductionnelle de SIRT2, la phosphorylation de la sérine 25 (S25), ciblée spécifiquement par l'infection, et essentielle pour l'association de SIRT2 à la chromatine. Nous avons caractérisé le complexe moléculaire impliqué dans la déphosphorylation de SIRT2-S25 et nous montrons que cette modification est essentielle pour contrôler la fonction de SIRT2 en tant que répresseur transcriptionnel, et est nécessaire pour une infection efficace. Notre approche protéomique a aussi permis la caractérisation d'un interactome de SIRT2. De nombreuses protéines ont été identifiées et quelques-unes ont été confirmées et étudiées pour leur rôle dans le transport nucléo-cytoplasmique de SIRT2. De plus, une collaboration au laboratoire a mis au jour un mécanisme de subversion de la réponse aux dommages de l'ADN de l'hôte par Listeria. Dans son ensemble, ce travail a contribué à la compréhension de mécanismes originaux de l’interaction entre les bactéries et la chromatine et a révélé un processus cellulaire contrôlant la localisation subcellulaire et la fonction de la protéine de l’hôte SIRT2. / One of the best model organisms for the study of bacterial-host interactions is Listeria monocytogenes. This facultative intracellular pathogen can infect, survive, and replicate in the cytoplasm of eukaryotic cells, demonstrating the close co-evolution of Listeria with itshost. The intracellular life style of this pathogen involves manipulation of various host cellcomponents, one of which is chromatin. By inducing chromatin modifications at the level of histones, Listeria can influence the transcriptional program of the host. This thesis focuses on one specific histone modification, deacetylation of histone H3 of lysine 18, which is induced by the host deacetylase Sirtuin 2 (SIRT2) upon its relocalization from the cytoplasmto the nucleus during infection. Hijacking of SIRT2 by Listeria provides an ideal system tostudy the mechanisms of SIRT2 subcellular localization, which is poorly understood, and is the purpose of this thesis. By using mass spectrometry we have identified a novel posttranslational modification of SIRT2, Serine 25 (S25) phosphorylation, specifically targeted byinfection, and essential for SIRT2 chromatin association. We have characterized themolecular complex involved in dephosphorylating SIRT2-S25 and we show that this modification is essential for controlling SIRT2 function as a transcriptional repressor andnecessary for productive infection. Our proteomic approach further allowed the characterization of a SIRT2 interactome. Many proteins were identified and a few wereconfirmed and studied for their role in nucleo-cytoplasmic shuttling of SIRT2. In addition, a laboratory collaboration uncovered a mechanism for subversion of the host DNA DamageResponse by Listeria. As a whole, this work has contributed to the understanding of original mechanisms of chromatin-bacteria cross talk, and has revealed a cellular process controlling subcellular localization and function of the host protein SIRT2.

Stem cells are defined by their capacity to self-renew and their potential to differentiate into multiple cell lineages. Pluripotent embryonic stem (ES) cells can renew indefinitely while keeping the potential to differentiate into any of the three germ layers (ectoderm, endoderm or mesoderm). For decades, ES cells are in the focus of research because of these unique features. When ES cells differentiate they form spheroid aggregates termed “embryoid bodies” (EBs). These EBs mimic post- implantation embryonic development and therefore facilitate the understanding of developmented mechanisms. During ES cell differentiation, de-repression or repression of genes accompanies the changes in chromatin structure. In ES cells, several mechanisms are involved in the regulation of the chromatin architecture, including post-translational modifications of histones. Post-translational histone methylation marks became one of the best- investigated epigenetic modifications, and they are essential for maintaining pluripotency. Until the first histone demethylase KDM1A was discovered in 2004 histone modifications were considered to be irreversible. Since then, a great number of histone demethylases have been identified. Their activity is linked to gene regulation as well as to stem cell self-renewal and differentiation. KDM6A and KDM6B are H3K27me3/2-specific histone demethylases, which are known to play a central role in the regulation of posterior development by regulating HOX gene expression. So far less is known about the molecular function of KDM6A or KDM6B in undifferentiated and differentiating ES cells. In order to completely abrogate KDM6A and KDM6B demethylase activity in undifferentiated and differentiating ES cells, a specific inhibitor (GSK-J4) was employed. Treatment with GSK-J4 had no effect on the viability or proliferation on ES cells. However, in the presence of GSK-J4 ES cell differentiation was completely abrogated with cells arrested in G1-phase and an increased rate of apoptosis. Global transcriptome analyses in early-differentiating ES cells revealed that only a limited set of genes were differentially regulated in response to GSK-J4 treatment with more genes up- regulated than down-regulated. Many of the up-regulated genes are linked to DNA damage response (DDR). In agreement with this, DNA damage was found in EBs incubated with GSK-J4. A co-localization of H3K27me3 or KDM6B with γH2AX foci, marking DNA breaks, could be excluded. However, differentiating Eed knockout (KO) ES cells, which are devoid of the H3K27me3 mark, showed an attenuated GSK-J4- induced DDR. Finally, hematopoietic differentiation in the presence of GSK-J4 resulted in a reduced colony-forming potential. This leads to the conclusion that differentiation in the presence of GSK-J4 is also restricted to hematopoietic differentiation. In conclusion, my results show that the enzymatic activity of KDM6A and KDM6B is not essential for maintaining the pluripotent state of ES cells. In contrast, the enzymatic activity of both proteins is indispensable for ES cell and hematopoietic differentiation. Additionally KDM6A and KDM6B enzymatic inhibition in differentiating ES cells leads to increased DNA damage with an activated DDR. Therefore, KDM6A and KDM6B are associated with DNA damage and in DDR in differentiating ES cells. / Stammzellen sind definiert durch ihre Fähigkeit zur Selbsterneuerung und dem Potential in multiple Zellinien zu differenzieren. Pluripotente embryonale Stammzellen (ES Zellen) können sich fortlaufend erneuern und besitzen zudem das Potential, in alle drei Keimblätter (Ektoderm, Endoderm oder Mesoderm) zu differenzieren. Auf Grund dieser einzigartigen Eigenschaften sind ES Zellen seit Jahrzehnten im Focus der Wissenschaft. Wenn ES Zellen differenzieren, sind sie in der Lage, sphäroid-förmige Aggregate zu bilden, welche als embryoide Körperchen (EBs) bezeichnet werden. In EBs finden sich Zellen aller 3 Keimblätter und daher dienen sie als in vitro Modell für frühe embryonale Entwicklung. Während der ES Zell Differenzierung verändert die De-repression oder Repression von Genen die Struktur des Chromatins. ES Zellen besitzen eine Vielzahl von Mechanismen, die mit der Regulation des Chromatins assoziiert sind, einschließlich post-translationale Modifikationen an Histonen. Post-translationale Histon- methylierung gehören zu den am häufigsten untersuchten epigenetischen Modifikationen und spielen z.B. ein wichtige Rolle bei der Aufrechterhaltung der Pluripotenz. Bis zur Entdeckung der ersten Histon-Demethylase KDM1A im Jahre 2004 glaubte man, dass Modifikationen an Histonen irreversible sind. Bislang wurden jedoch eine Vielzahl an Histon-Demethylasen identifiziert, welche mit der Genregulation, sowie der Selbsterneuerung und Differenzierung von Stammzelle in Verbindung gebracht werden konnten. KDM6A und KDM6B sind H3K27me3/2-spezifische Histon-Demethylasen, welche bei der posterioren Entwicklung durch Regulation der Hox Gene eine wichtige Rolle spielen. Bislang ist über die molekulare Funktion von KDM6A und KDM6B in nicht differenzierten und differenzierenden ES Zellen wenig bekannt. Um die KDM6A und KDM6B Demethylase Aktivität in nicht differenzierten und differenzierenden ES Zellen außer Kraft zu setzten kam ein spezifischer Inhibitor (GSK-J4) zum Einsatz. Die Behandlung mit GSK-J4 zeigte keine Auswirkungen auf die Viabilität oder Proliferation von nicht differenzierten ES Zellen. Jedoch war die Differenzierung von ES Zellen in Gegenwart von GSK-J4 inhibiert und zeigte einen erhöhten G1-Phase Arrest sowie eine erhöhte Rate an apoptotischen Zellen. Eine globale Transkriptionsanalyse in frühen differenzierenden ES Zellen, in Gegenwart von GSK- J4 zeigte, dass lediglich eine relativ geringe Zahl von Genen differenziell reguliert war. Dabei waren mehr Gene hochreguliert als herunterreguliert. Viele der hochregulierten Gene konnten mit der DNA Schadensantwort in Verbindung gebracht werden. In Übereinstimmung damit konnte in Gegenwart von GSK-J4 in differenzierenden ES Zellen DNA Schaden nachgewiesen werden. Eine Kolokalisation von H3K27me3 oder KDM6B mit γH2AX markierten Foci, welche DNA Schaden markieren, konnte nicht nachgewiesen werden. Nichts desto trotz zeigten GSK-J4 behandelte, differenzierende Eed KO ES Zellen, welche keine H3K27me3 Modifikation besitzen, eine abgemilderte DNA Schadensantwort. In Anwesenheit von GSK-J4 konnte während der hämatopoetischen Differenzierung eine reduzierte Kolonie-Bildung beobachtet werden. Daraus lässt sich schließen, dass in Anwesenheit von GSK-J4 ebenfalls auch die hämatopoetische Differenzierung inhibiert wird. Zusammenfassend zeigen meine Ergebnisse, dass die enzymatische Aktivität von KDM6A und KDM6B für die Aufrechterhaltung des pluripotenten Zustands nicht essenziell ist. Im Gegensatz dazu ist die enzymatische Aktivität von beiden Proteinen unabdingbar für die ES Zell sowie die hämatopoetische Differenzierung. Die enzymatische Inhibierung von KDM6A und KDM6B führt während der Differenzierung zu einem erhöhten DNA Schaden, wodurch die DNA Schadensantwort aktiviert wird. Somit sind KDM6A und KDM6B mit DNA Schaden und der DNA Schadensantwort assoziiert.

Le genre Legionella regroupe des bactéries pouvant causer chez l'homme une pneumonie fatale dans 10% des cas, la légionellose. Elles sont capables de coloniser tous les réseaux d'eau. Le génome de ces bactéries révèle une forte plasticité génomique, aux niveaux fonctionnel et structural. La première partie de cette thèse analyse l'impact des protéines de type histone sur la régulation de la virulence chez L. pneumophila. Ces protéines structurent le chromosome bactérien et influencent l'expression génique. Des mutants des gènes codant les protéines Dps et IHF ont été obtenus chez L. pneumophila et analysés pour leur sensibilité aux stress et leurs propriétés de virulence. Ces deux protéines sont impliquées dans la régulation de la virulence chez Legionella. De plus, Dps permet de diminuer la sensibilité au stress oxydatif et IHF régulerait l'entrée dans l'état VBNC (viable but non-culturable), un état physiologique dans lequel les bactéries sont viables mais ne sont plus cultivables. La seconde partie vise à utiliser la plasticité structurale, notamment celle induite par les éléments génétiques mobiles IS, comme outil épidémiologique. A l'heure actuelle, les méthodes d'identification ne permettent pas de discriminer les isolats de même espèce. Afin d'éviter de nouvelles contaminations, il est impératif d'identifier rapidement et avec précision l'installation contaminée, à partir des prélèvements de patients comme élément comparatif. L'utilisation d'une méthode RFLP-IS a permis de mettre en évidence une IS particulière, ISLpn11, possédant un taux de discrimination de 80% au sein de la souche L. pneumophila Paris, qui est responsable de plus de 10 % des épidémies en Europe.

Targeting the epigenome, including the use of histone deacetylase (HDAC) inhibitors, is a novel strategy for cancer chemoprevention. Sulforaphane (SFN), a compound found at high levels in broccoli and broccoli sprouts, is a potent inducer of Phase 2 detoxification enzymes and inhibits tumorigenesis in animal models. SFN also has a marked effect on cell cycle checkpoint controls and cell survival/apoptosis in various cancer cells, through mechanisms that are poorly understood. Based on the structure of known histone deacetylase inhibitors, it was hypothesized that SFN may possess HDAC inhibitory properties. Initial studies confirmed that, indeed, at physiologically-relevant concentrations, SFN inhibited HDAC activity in human colorectal cancer cells, with a concomitant increase in acetylated histones H3 and H4, induction of p21 expression, and increased acetylated histone H4 associated with the P21 promoter. A metabolite of SFN, SFN-Cysteine, was found to be the active HDAC inhibitor. Furthermore, in BPH-1, LnCaP, and PC-3 human prostate epithelial cells, SFN inhibited HDAC activity and increased acetylation of histones. SFN also induced p21 expression, with an increase in acetylated histone H4 associated with the P21 promoter in BPH-1 cells. The downstream effects of HDAC inhibition by SFN included induction of pro-apoptotic proteins and repression of anti-apoptotic proteins, and an increase in multi-caspase activity. Dietary SFN suppressed the growth of human prostate cancer PC-3 xenografts and inhibited HDAC activity in the xenografts, peripheral blood mononuclear cells (PBMC), and prostates. In time-course studies, a single oral dose of SFN induced histone acetylation at 6 and 24 h in mouse colonic mucosa, and long-term dietary SFN treatment increased histone acetylation in the ileum, colon, PBMC, and prostates. Moreover, dietary SFN suppressed intestinal tumorigenesis significantly in Apc[superscrip min] mice, with an increase in acetylated histones detected in the normal-looking ileum and polyps and polyps from the colon. Overall, the data presented in this thesis support a novel mechanism for chemoprevention by SFN in vivo, through inhibition of histone deacetylase. The findings also imply that SFN will offer significant protection against at least two of the major cancer killers in the US, namely colon and prostate cancer. / Graduation date: 2005

Histone Deacetylase (HDAC) plays a vital role in cellular processes, for example gene expression, cell growth, and apoptosis. Finding drug candidates to inhibit the over activity of HDACs in cancer is a growing area of interest. Inhibitors, thus far, have three important motifs to be studied: the zinc binding group, a hydrophobic linker, and a cap group. By altering these groups on the inhibitor, not only can activity be increased but also selectivity within the classes of HDACs. We present the design of two novel sets of molecules that contain either a 1,2,3-triazole or 1,2,4-triazole. The 1,2,3-triazoles were synthesized using “click chemistry” with a novel pyridyl triazine catalyst. The 1,2,4-triazoles were synthesized utilizing substitution chemistry. This set of molecules was designed after suberoylanilide hydroxamic acid (SAHA) but replaced the hydroxamate with the triazole as the zinc binding group. The activity of these inhibitors against HDAC 1, HDAC 6, and SIRT 1 were tested using the Biomol Fluor de Lys in vitro kits. Though none of the synthesized compounds were strong activators or inhibitors of any of the classes of HDACs, trends were observed that could lead to the design of more potent inhibitors.

Thesis (Ph. D.)--Ohio State University, 2006. / Title from first page of PDF file. Includes bibliographical references (p. 115-136).

Friedreich’s ataxia (FRDA) is an inherited recessive disorder characterized by progressive neurological disability and heart disease. It is caused by a pathological intronic hyperexpansion of a GAA repeat in the FXN gene, encoding the essential mitochondrial protein frataxin. At the homozygous state, the GAA expansion induces a heterochromatin state with decreased histone acetylation and increased methylation, resulting in a partial deficiency of frataxin expression. This was established in cells from FRDA patients. We showed that the same chromatin changes exist in a GAA based mouse model, KIKI, generated in our laboratory. Furthermore, treatment of KIKI mice with a novel Histone Deacetylase Inhibitor (HDACi), 106, a pimelic diphenylamide that increases frataxin levels in FRDA cell culture, restored frataxin levels in the nervous system and heart of KIKI mice and induced histone hyperacetylation near the GAA repeat. As shown by microarrays, most of the differentially expressed genes in KIKI were corrected towards wild type. In an effort to improve the pharmacological profile of compound 106, we synthesized more compounds based on its structure and specificity. We characterized two of these compounds in FRDA patients’ peripheral blood lymphocytes and in the KIKI mouse model. We observed a sustained frataxin upregulation in both systems, and, by following the time course of the events, we concluded that the effects of these compounds last longer than the time of direct exposure to HDACi. Our results support the pre-clinical development of a therapeutic approach based on pimelic diphenylamide HDACis for FRDA. Laboratory tools to follow disease progression and assess drug efficacy are needed in a slowly progressive neurodegenerative disease such as FRDA. We used microarrays to characterize the gene expression profile in peripheral lymphocytes from FRDA patients, carriers and controls. We identified gene expression changes in heterozygous, clinically unaffected GAA expansion carriers, suggesting that they present a biochemical phenotype, consistent with data from animal models of frataxin deficiency. We identified a subset of genes changing in patients as a result of pathological frataxin deficiency establishing robust gene expression changes in peripheral lymphocytes. These changes can be used as a biomarker to monitor disease progression and potentially assess drug efficacy. To this end, we used he same methodology to characterize the gene expression profiles in peripheral lymphocytes after treatment with pimelic diphenylamide HDACi. This treatment had relevant effects on gene expression on peripheral patients’ blood lymphocytes. It increased frataxin levels in a dose-dependent manner, and partially rescued the gene expression phenotype associated with frataxin deficiency in the tested cell model, thus providing the first application of a biomarker gene set in FRDA.

The development of animals and plants needs a higher order of regulation of gene expression to maintain proper cell state. The mechanisms that control what, when and where a gene should (or should not) be expressed are essential for correct organism development. The Polycomb group (PcG) is a family of genes responsible for maintaining gene silencing and Suppressor of zeste 12 (Su(z)12) is one of the core components in the PcG. The gene is highly conserved in organisms ranging from plants to humans, however, the specific function is not well known. The main tasks of this thesis was to investigate the function of Su(z)12 and its expression at different stages of Drosophila development. In polytene chromosomes of larval salivary glands, Su(z)12 binds to about 90 specific euchromatic sites. The binding along the chromosome arms is mostly in interbands, which are the most DNA de-condensed regions. The binding sites of Su(z)12 in polytene chromosomes correlate precisely with those of the Enhancer-of-zeste (E(z)) protein, indicating that Su(z)12 mainly exists within the Polycomb Repressive Complex 2 (PRC2). However, the binding pattern does not overlap well with Histone 3 lysine 27 tri-methylations (H3K27me3), the specific chromatin mark created by PRC2. The Su(z)12 binding to chromatin is dynamically regulated during mitotic and meiotic cell division. The two different Su(z)12 isoforms: Su(z)12-A and Su(z)12-B (resulting from alternative RNA splicing), have very different expression patterns during development. Functional analyses indicate that they also have different functions he Su(z)12-B form is the main mediator of silencing. Furthermore, a neuron specific localization pattern in larval brain and a giant larval phenotype in transgenic lines reveal a potential function of Su(z)12-A in neuron development.  In some aspects the isoforms seem to be able to substitute for each other. The histone methyltransferase activity of PRC2 is due to the E(z) protein. However, Su(z)12 is also necessary for H3K27me3 methylation in vivo, and it is thus a core component of PRC2. Clonal over-expression of Su(z)12 in imaginal wing discs results in an increased H3K27me3 activity, indicating that Su(z)12 is a limiting factor for silencing. When PcG function is lost, target genes normally become de-repressed. The segment polarity gene engrailed, encoding a transcription factor, is a target for PRC2 silencing. However, we found that it was not activated when PRC2 function was deleted. We show that the Ultrabithorax protein, encoded by another PcG target gene, also acts as an inhibitor of engrailed and that de-regulation of this gene causes a continued repression of engrailed. The conclusion is that a gene can have several negative regulators working in parallel and that secondary effects have to be taken into consideration, when analyzing effects of mutants. PcG silencing affects very many cellular processes and a large quantity of knowledge is gathered on the overall mechanisms of PcG regulation. However, little is known about how individual genes are silenced and how cells “remember” their fate through cell generations.

Understanding the specific mechanisms regulating chemotherapeutic drug anti-cancer activities will uncover novel strategies to enhance the efficacy of these drugs in clinical settings. Activating Transcription Factor 3 (ATF3) is a stress inducible gene whose expression has been associated with survival outcomes in cancer models. This study characterizes the chemotherapeutic drugs, cisplatin and Histone Deacetylase Inhibitor (HDACi), M344 as novel inducers of ATF3 expression. Cisplatin is a DNA damaging agent widely used in various tumour types including lung, head and neck, and ovarian carcinomas. The HDAC inhibitor, SAHA, has recently been approved as a single agent in the treatment of subcutaneous T-cell lymphoma and HDACis themselves show potential for synergistic anti-cancer effects when used in combination with established chemotherapeutic drugs, including cisplatin. This study evaluates the mechanisms by which cisplatin and HDACi induce ATF3, as well as the role ATF3 plays as a mediator of cisplatin-induced cytotoxicity and the enhanced cytotoxicity between HDACi and cisplatin in combination. In this study, we demonstrate that cytotoxic doses of cisplatin and carboplatin consistently induced ATF3 expression in a panel of human tumour derived cell lines. Characterization of this induction revealed a p53, BRCA1, and integrated stress response (ISR) independent mechanism, all previously implicated in stress mediated ATF3 induction. Analysis of MAPKinase pathway involvement in ATF3 induction by cisplatin revealed a MAPKinase dependent mechanism. Cisplatin treatment, in combination with specific inhibitors to each MAPKinase pathway (JNK, ERK and p38) resulted in decreased ATF3 induction at the protein level. MAPKinase pathway inhibition led to decreased ATF3 mRNA expression and a reduction in the cytotoxic effects of cisplatin as measured by MTT cell viability assay. In A549 lung carcinoma cells, targeting ATF3 with specific shRNAs also attenuated the cytotoxic effects of cisplatin. Similarly, ATF3 -/- MEFs were shown to be less sensitive to cisplatin induced cytotoxicity as compared with ATF3+/+ MEFs. Taken together, we identified cisplatin as a MAPKinase pathway dependent inducer of ATF3 whose expression regulates in part cisplatin’s cytotoxic effects. Furthermore, we demonstrated that the HDAC inhibitor M344 was also an inducer of ATF3 expression at the protein and mRNA level in the same human derived cancer cell lines. Combination treatment with M344 and cisplatin lead to increased induction of ATF3 compared with cisplatin alone. Utilizing the MTT cell viability assay, M344 treatment was also shown to enhance the cytotoxic effects of cisplatin in these cancer cell lines. Unlike cisplatin, the mechanism of ATF3 induction by M344 was found to be independent of MAPKinase pathways. Utilizing ATF4 heterozygote (+/-) and knock out (-/-) mouse embryonic fibroblast (MEF) M334 induction of ATF3 was shown to depend on the presence of ATF4, a known regulator of ATF3 expression as part of the ISR pathway. HDACi treatment did not affect the level of histone acetylation associated with the ATF3 promoter as determined through Chromatin immunoprecipitation (ChIP) analysis, suggesting that ATF3 induction was not a direct effect of HDACi mediated histone acetylation. We also demonstrated that ATF3 regulates the enhanced cytotoxicity of M344 in combination with cisplatin as evidenced by attenuation of cytotoxicity in shRNAs targeting ATF3 expressing cells. This study identifies the pro-apoptotic factor, ATF3 as a novel target of M344, as well as a mediator of the co-operative effects of cisplatin and M344 induced tumour cell cytotoxicity.

Epigenetic mechanisms are essential for normal cell development. Alteration in those normal processes leads to malignant cell transformation and with this to cancer development. Use of inhibitors that alter the epigenetics of DNA methylation and histone post translational modifications has lead to the exploration of the epigenetic mechanism involved in silencing of tumor suppressor genes in cancer, including acute myeloid leukemia (AML). Moreover, combinations of inhibitors that target various epigenetic enzymes have being recognized to be more effective in the re-activation of tumor suppressor genes than individual drug treatments. Here, we reported that p15, p21 and E-cadherin genes are more effectively re-expressed using a combination of DNA methyltransferase and histone methyltransferase inhibitors in AML cell lines. Re-expression of hypermethylated p15 and E-cadherin genes required reduced levels of promoter histone 3 lysine 9 (H3K9) methylation rather than inhibition of DNA methylation itself. Moreover, induction of p21 expression was associated with changes in promoter histone 3 lysine 9 methylation (H3K9Me) by achieving inhibition of the histone methyltransferase, SUV39H1, activity. Altogether, our results highlight the potential of combining epigenetic drugs in the re-activation of epigenetically silenced tumor suppressor genes and the need for evaluating histone methyltransferases as therapeutic targets for treatment of acute myeloid malignancies.